Clinical Trial in Males With BPH (Enlarged Prostate)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00029822|
Recruitment Status : Completed
First Posted : January 24, 2002
Last Update Posted : June 9, 2008
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH.
- Free study-related medical care provided.
|Condition or disease||Intervention/treatment||Phase|
|Urinary Retention Prostatic Hyperplasia Benign Prostatic Hypertrophy||Drug: Alfuzosin (SL770499)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1522 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.|
|Study Start Date :||May 2001|
|Actual Study Completion Date :||March 2005|
- occurrence of first episode of acute urinary retention (AUR)
- need for benign prostatic hyperplasia (BPH)-related surgery, international prostate symptoms score (IPSS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029822
|Study Director:||ICD CSD||Sanofi|